Farhan Mohammed, I., Motawa, I., Abd El Monem Aly, M., Mohammed Metwally,, M. (2018). Assessment of Interleukin (8) in Type 2 Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 72(4), 4403-4406. doi: 10.21608/ejhm.2018.9298
Ihab Nehad Farhan Mohammed; Ilham Aly Motawa; Mekky Abd El Monem Aly; Mahmoud Mohammed Mohammed Metwally,. "Assessment of Interleukin (8) in Type 2 Diabetes Mellitus". The Egyptian Journal of Hospital Medicine, 72, 4, 2018, 4403-4406. doi: 10.21608/ejhm.2018.9298
Farhan Mohammed, I., Motawa, I., Abd El Monem Aly, M., Mohammed Metwally,, M. (2018). 'Assessment of Interleukin (8) in Type 2 Diabetes Mellitus', The Egyptian Journal of Hospital Medicine, 72(4), pp. 4403-4406. doi: 10.21608/ejhm.2018.9298
Farhan Mohammed, I., Motawa, I., Abd El Monem Aly, M., Mohammed Metwally,, M. Assessment of Interleukin (8) in Type 2 Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 2018; 72(4): 4403-4406. doi: 10.21608/ejhm.2018.9298
Assessment of Interleukin (8) in Type 2 Diabetes Mellitus
Department of Clinical Pathology, Al-Hussein University Hospital, Al-Azhar Faculty of Medicine
Abstract
Background: Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long- term damage, dysfunction, and failure of different organs, especially the eyes, kidneys, nerves, heart, and blood vessels. Type 2 diabetes (T2D) is characterized by a condition of systemic low-grade inflammation. IL-8 is an important member of the chemokine family of proinflammatory chemotactic cytokines. IL-8 was initially characterized as a potent chemoattractant of neutrophils and was later shown to also activate neutrophils. IL-8 is also known to be a potent promoter of angiogenesis. Objective: It was the Assessment of Interleukin (8) in Type 2 Diabetes Mellitus. Patients and Methods: Serum IL 8 level in Type 2 Diabetes Mellitus. 30 patients compared to 30 normal individuals were included in this study. Results: There was a highly statistical significant difference between all patients and control groups as regard serum IL 8 level (mean of serum IL 8 in patients and control groups were 69.9 ± 20.5 and 5.4 ± 3.3 respectively, p= < 0.001). Conclusion: Type 2 diabetes mellitus patients showed marked elevation of circulating IL-8 levels which identify subjects with worse inflammatory state and metabolic control and therefore it may be used as a marker for the rate of development of diabeteic complications.
View on SCiNiTO
Top